ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 548

Body Mass Index Is Positively Correlated with Diverse Disease Activity Measures in Longstanding Rheumatoid Arthritis

Craig Wiesenhutter, Coeur d'Alene Arthritis Clinic, Coeur D Alene, ID; University of Washington School of Family Medicine, Seattle, ID

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Activity score, body mass, rheumatoid arthritis (RA) and risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Obesity is a common problem with patients who have rheumatoid arthritis (RA). Adipose tissue has been shown to produce cytokines that are proinflammatory. The measurement of Body Mass Index (BMI) is a proxy for determining the amount of adipose tissue present in an individual. The impact of BMI on disease activity measures in RA have been contradictory, and, in fact, studies have shown that a high BMI is protective, as defined by x-ray changes for patients with early onset RA. The objective of this trial is to determine whether obesity and BMI are positively correlated with diverse disease activity measures (DAMs) in longstanding RA.

Methods: Patients at a community based rheumatology clinic undergo DAM assessments on a routine basis as part of the implementation of a treat to target (T2T) strategy. These assessments include the disease activity score in 28 joints (DAS28CRP), the power Doppler joint count (UPD), and the multibiomarker disease activity test (MBDA), as well as several other commonly assessed DAMs. The UPD includes scoring at six dorsal wrist and six dorsal MCP sites. The average duration of RA in patients at this clinic is > 10 years. Also, as currently mandated by the authorities, BMI and other vital signs are obtained on a regular basis. Correlations were determined by Pearson’s coefficients, and categorical data was compared by T tests. Patients were categorized as underweight (BMI < 18), normal weight (BMI > =18 and <25), overweight (BMI >=25 and <30), and obese (BMI >= 30).

Results: Table 1 BMI and Comparisons with Diverse Disease Activity Measures

 

 

 

 

Normal Wt

Overweight

Obese

Prob

Prob

Prob

N

BMI VS

Prob

Avg +/- SD

Avg +/- SD

Avg +/- SD

Nl vs Over

Nl vs Obese

Over vs Obese

Leptin

241

r=572

p<0.0001

11.8 +/- 19.7

19.2 +/- 18.4

30.4 +/- 23.9 

p=0.01

p<0.0001

p<0.0001

DAS28CRP

260

r=537

p<0.0001

3.63 +/- 1.62

3.86 +/- 1.24

4.47 +/- 1.32

NS

p<0.0001

p<0.0001

DAS28ESR

236

r=285

p<0.005

4.11 +/- 1.38

4.10 +/- 1.45

4.47 +/- 1.32

NS

NS

p<0.0001

CRP

238

r=340

p<0.0001

4.6 +/- 13.8

7.2 +/- 15.1

6.0 +/- 8.9

NS

NS

NS

ESR

236

r=289

p<0.0001

18.3 +/- 13.7

19.0 +/- 20.4

21.9 +/- 19.4

NS

NS

p=0.02

MBDA

242

r=300

p<0.0001

37.7 +/- 13.6

40.6 +/- 16.2

41.3 +/- 12.7

NS

p=0.05

p<0.0001

HAQ

233

r=289

p<0.0001

1.9 +/- 1.6

1.8 +/- 1.4

2.7 +/- 1.8

NS

p=0.02

p=0.02

Pt Global

229

r=228

p<0.001

3.5 +/- 2.4

3.5 +/- 2.2

5.0 +/- 2.3

NS

NS

p<0.0001

TJC

271

r=222

p<0.001

7.1 +/- 6.8

7.6 +/- 9.7

11.4 +/- 7.5

NS

p=0.003

p<0.0001

CDAI

236

r=206

p<0.001

18.6 +/- 12.2

19.0 +/- 20.4

21.9 +/- 19.4

NS

p<0.001

p=.003

RAPIDIII

244

r=224

p<0.001

8.9 +/- 6.0

8.3+/- 5.1

11.4 +/- 7.5

NS

NS

p=0.02

There were only two patients in the underweight category, and that category was not included in this analysis.

Conclusion: BMI positively correlates with, and shows significant increases in weight categories for several important measures of disease activity in patients with longstanding RA. Though the DAS28CRP, MBDA, and UPD generally correlate significantly in this clinic (r= > 0.500), in this study, UPD was the only one of these measures that did not correlate with BMI (r = 0.090). One possible explanation is that power Doppler signals are very dependent on the distance of the probe from the site of the signal. The UPD method utilized includes assessments of the dorsal wrist at six out of twelve sites. Subcutaneous adipose tissue in overweight patients perhaps blunted the signals. Of interest, Leptin was significantly correlated with BMI and showed significant increases with weight categories. Leptin is produced by adipose tissue and is thought to be proinflammatory. Excess Leptin production might be contributory to the effects of BMI on RA disease activity. BMI is positively correlated with several important DAMs in patients with longstanding RA. Rheumatologists should significantly increase their efforts and resources to address and manage obesity in our RA patients.  


Disclosure: C. Wiesenhutter, None;

To cite this abstract in AMA style:

Wiesenhutter C. Body Mass Index Is Positively Correlated with Diverse Disease Activity Measures in Longstanding Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/body-mass-index-is-positively-correlated-with-diverse-disease-activity-measures-in-longstanding-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/body-mass-index-is-positively-correlated-with-diverse-disease-activity-measures-in-longstanding-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology